Raxibacumab

The drug candidate, called raxibacumab or ABthrax, is aimed at treated inhaled anthrax. ❋ Unknown (2009)

The Company's products are BENLYSTA (belimumab) for systemic lupus erythematosus (SLE) and raxibacumab for inhalation anthrax.

Revenue gains were led by $19.1 million in payments from partner Novartis for continued development of its hepatitis C treatment, Zalbin and $13.1 million in sales of raxibacumab to the U.S. stockpile. ❋ Unknown (2010)

In April 2009, HGS completed the delivery of 20,000 doses of raxibacumab to the U.S. ❋ Unknown (2010)

The local biotech earned its first product sales revenue this year through HHS contracts, topping $300 million in all, by selling tens of thousands of raxibacumab doses toward the national stockpile. ❋ Unknown (2009)

That product could compete with raxibacumab, formerly called ABThrax, that Human Genome Sciences has been developing, also to treat inhaled anthrax. ❋ Unknown (2009)

But Human Genome Sciences hit a bump in its commercial path for raxibacumab last month when the Food and Drug Administration declined to approve the drug, saying it still had questions about how well it worked compared to existing drugs. ❋ Unknown (2009)

ABthrax (TM) (raxibacumab) is in late-stage development for inhalation anthrax, and the Company is awaiting authorization to begin delivery of ABthrax to the U.S. ❋ Unknown (2009)

In January 2009, HGS began delivery of 20,000 doses of ABthrax (TM) (raxibacumab) to the U.S. ❋ Unknown (2009)

"The results published today showed that a single dose of raxibacumab was highly effective as a treatment for inhalation anthrax in both rabbits and monkeys," said D. Sally D. June 12th, 2009 WASHINGTON - A polyphenol present in red wine, called resveratrol, has been found to have a large number of health benefits for drinkers, say researchers. ❋ Unknown (2009)

In May 2009, HGS submitted a Biologics License Application to the FDA for raxibacumab for the treatment of inhalation anthrax. ❋ Unknown (2009)